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Abstract 
Critical care, like many healthcare areas, is under a dual assault from significantly 
increasing demographic and economic pressures. Intensive care unit (ICU) patients 
are highly variable in response to treatment, and increasingly aging populations mean 
ICUs are under increasing demand and their cohorts are increasingly ill. Equally, patient 
expectations are growing, while the economic ability to deliver care to all is declin‑
ing. Better, more productive care is thus the big challenge. One means to that end is 
personalised care designed to manage the significant inter‑ and intra‑patient variability 
that makes the ICU patient difficult. Thus, moving from current “one size fits all” protocol‑
ised care to adaptive, model‑based “one method fits all” personalised care could deliver 
the required step change in the quality, and simultaneously the productivity and cost, 
of care. Computer models of human physiology are a unique tool to personalise care, 
as they can couple clinical data with mathematical methods to create subject‑specific 
models and virtual patients to design new, personalised and more optimal protocols, 
as well as to guide care in real‑time. They rely on identifying time varying patient‑
specific parameters in the model that capture inter‑ and intra‑patient variability, the 
difference between patients and the evolution of patient condition. Properly validated, 
virtual patients represent the real patients, and can be used in silico to test different 
protocols or interventions, or in real‑time to guide care. Hence, the underlying models 
and methods create the foundation for next generation care, as well as a tool for safely 
and rapidly developing personalised treatment protocols over large virtual cohorts 
using virtual trials. This review examines the models and methods used to create virtual 
patients. Specifically, it presents the models types and structures used and the data 
required. It then covers how to validate the resulting virtual patients and trials, and 
how these virtual trials can help design and optimise clinical trial. Links between these 
models and higher order, more complex physiome models are also discussed. In each 
section, it explores the progress reported up to date, especially on core ICU therapies 
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in glycemic, circulatory and mechanical ventilation management, where high cost and 
frequency of occurrence provide a significant opportunity for model‑based methods 
to have measurable clinical and economic impact. The outcomes are readily general‑
ised to other areas of medical care.
Background
Intensive care unit (ICU) patients are very difficult to manage safely, effectively and effi-
ciently due to complex and highly variable response to therapy. The cost of intensive care 
and treatment has risen greatly, primarily due to aging demographics and increasing 
average life spans (e.g. [1, 2]). In particular, the ability to maintain or improve the equity 
of access to care is increasingly important and difficult [3–8]. Thus, the major current 
challenge for ICU care is to improve cost and productivity. In this context, the personali-
sation of care to better capture the intra- and inter-patient variability in core ICU thera-
pies offers an opportunity to make a significant impact on both the quality and cost of 
care. In particular, changing from current “one size fits all” protocolised care, which can 
be problematic in the ICU [9–11], to a “one method fits all” personalised care, based on 
physiological models, could provide one significant change to address the demographic 
tsunami of rising demand and costs.
Computational methods have revolutionised the quality and productivity of output in 
a wide range of industries over the last two decades, but not nearly so much in medicine 
[7, 12, 13], where the ability to pay the increasing costs is declining [14]. In ICU medi-
cine, computational physiological models offer a major opportunity to personalise care, 
combining medical data and model identification methods to generate a “virtual patient” 
that represents a specific patient in a particular state relative to the system modelled (e.g. 
metabolic, cardiovascular, pulmonary). In addition, computational methods can draw on 
an increasing range of physiological models, methods and databases, ranging from sim-
ple to detailed and multi-scale models (e.g. [15–47]), which could be used as a founda-
tion for translating computer methods to critical care.
The overall approach relies on the ability to identify patient-specific parameters from 
data that are both patient-specific and time-varying, and thus manage the intra- and 
inter-patient variability that defines the typical ICU patient. As a result, such “sensi-
tivities” can be the key to virtual patients and personalised model-based care, as they 
provide an input–output relationship that reflects patient status and response to the 
treatment, as well as a metric that can then be used to titrate dose and thus care. Hence, 
this approach defines the use of deterministic physiological models, and could thus 
delineate more complex anatomically and biophysically based models (referred to from 
now on as ‘physiome models’) to an informative role, while capitalising upon simpler 
models for immediate use at the bedside (referred to from here on as ‘bedside models’).
In particular, physiome models have the detail and extensive dynamics to provide sig-
nificant insight into dysfunction at levels that bedside models, with their simpler single 
organ and/or single system dynamics, cannot [27, 30, 33, 38, 48–58]. Physiome models 
can also be made patient-specific. However, this task requires significant, often inva-
sive amounts of data, which are precluded by the time and immediacy of the critical 
care bedside. Finally, while computational tools are advancing and becoming standard-
ised [16, 31, 59–64], the computational intensity and number of variables can preclude 
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direct, immediate use to personalise and guide care, while enhancing the ability to simu-
late a range of detailed dysfunction. Thus, the physiological scale and/or complexity of 
physiome models can limit their immediate impact and patient specificity, particularly if 
the patient-specific condition varies rapidly.
In contrast, the loss of detail in bedside models may hide critical information by lump-
ing it into broader parameters or estimations. There is thus a role for both levels of mod-
eling to integrate and inform each other. Hence, while this review focuses predominantly 
on the emerging use of bedside, highly patient-specific models and virtual patients, the 
potential links to physiome models, well reviewed elsewhere [33, 48, 57, 58, 63, 65–68], 
are also presented.
Bedside models that capture specific fundamental dynamics have long been applied in 
physiological studies, but are far less used in clinical application, particularly in critical 
care. However, over the last 10 years, the growing number of model-based sensors or 
decision support systems in critical care (e.g. [69–90]) has surged, with their success-
ful design, validation and, in some cases, implementation as a standard of care. These 
results demonstrate the growing interest of using computational models to create per-
sonalised solutions to highly variable ICU patients.
Beyond their use in model-based bedside decision support, virtual patients based 
identified to measurement data are designed to represent the real patients. They can 
thus be used to design, test and compare different methods of care in silico, whether 
in real-time or in virtual protocol design. In particular, in silico patient-specific models 
provide a safe, rapid means to design, prototype and optimise treatment methods. Thus, 
virtual patients, and their underlying models and methods in particular, provide a tool 
for both design and implementation of personalised, model-based care.
In addition to safe, rapid protocol design and optimisation, virtual cohorts of virtual 
patients present the unique opportunity to improve on evidence-based ICU randomised 
controlled trials (RCTs). Those trials often focus on a single aspect of care or physiol-
ogy and are thus equally often compromised by lack of generality when clinically applied 
in general cohorts [91, 92]. The care of any specific dysfunction may be further con-
founded by a variety of related conditions, such as drug therapy or the body’s own reflex 
responses. Together, these issues have made designing and implementing effective ICU 
randomized clinical trials very difficult, making it difficult for the field to move forward 
as a whole [10, 91–98].
Virtual patients, cohorts and trials offer the potential to advance better solutions tak-
ing into account pathophysiological condition as well as intra- and inter-patient vari-
ability in response to care. These latter changes in patient state are difficult to control 
in a RCT as they cannot be predicted [91, 94, 95, 97]. However, they can be easily found 
retrospectively in clinical data, and thus tested virtually, in silico in designing a clini-
cal trial using a sufficiently broad virtual cohort. Thus, even before implementation one 
can verify a protocol is robust and safe in the face of inter- and intra-patient variability 
across a diverse, clinically typical cohort with multiple issues being treated. This capa-
bility would, in effect, permit a series of single patient clinical trials to be performed in 
silico, and to thus optimise a protocol to best manage significant variations in patient 
behaviour and thus performance.
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Hence, a validated in silico virtual trial platform, with associated proper virtual 
cohorts, would enable the elimination, or a reduction in the number, of phase II/III 
human trials. For regulatory submissions this potential to replace or augment human 
trials as an additional, accepted form of evidence is already partly realised [99, 100]. This 
use of virtual platforms to perform virtual trials shows the complementarity and effi-
ciency gains possible using both in silico and clinical trials to achieve a better or best 
outcome in a far more efficient manner with less patient burden.
Equally importantly, since virtual trials and patients can readily include device dynam-
ics or simulated clinical errors there is the further opportunity to better link device 
design and their clinical utilisation in care into both protocol and/or device design (e.g. 
[25, 101–105]). This point was well made in the case analysis by Viceconti et al. [100], 
reviewing the literature in this area, and showing two successful examples using virtual 
patients to develop new products. Thus, there is a critical role in product development 
for these types of models and methods.
Finally, and in particular, in a joint effort to develop novel devices, clinicians and medi-
cal device companies could also use them to develop optimised protocols using existing 
or new devices designed to fit into clinical workflow with minimal effort. This aspect 
is especially important wherever human factors at the interface of care and technology 
play a major role in protocol ease of use. The resulting improved compliance and clinical 
success, could significantly improve patient outcomes [106–111], by incorporating vir-
tual patients and trials analyses.
This review examines the computational methods and modeling necessary to design 
virtual patients. Especially, the models and data required are reviewed, and the different 
levels of validation possible for the resulting virtual patients are discussed. It also notes 
how virtual trials could be used to design not only protocols, but also to design and test 
clinical trials before implementation to try and ensure more robust results from these 
trials. Each section explores the results to date, with particular focus on core ICU thera-
pies managing metabolic, circulatory and pulmonary function. These three areas capture 
the desire to manage core ICU therapies around glycemic control, cardiovascular and 
circulatory management, and mechanical ventilation. In each case, variable management 
of these complex core therapies can be linked to worsened outcomes, increased patient 
length of stay and thus increased cost. Finally, before concluding, it addresses some of 
the future possible uses and implications of this emerging fusion of engineering and 
medical sciences.
Model types and requirements
A computational physiological model is a mathematical approximation of the observed 
physical, chemical and/or biological processes, containing certain assumptions in 
describing these processes. These models can vary significantly in complexity, based on 
the desired use, and range from simple-compartment models with few parameters (e.g. 
[18, 21–26, 28, 34–37, 45, 47]) to complicated multi-dimensional network representa-
tions or finite element models for similar systems or the entire body (e.g. [15–17, 19, 20, 
27, 29–33, 38, 55, 56, 112, 113]).
A virtual patient model (VPM) should have:
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  • Physiologically relevance.
  • Clinically relevance.
  • Identifiable treatment sensitivity.
And must also be:
•  Identifiable from the data available at the bedside or clinical situation.
Physiological relevance of a VPM requires a fixed structure representing the relevant 
physiological dynamics. While no model can reflect all observed complexity of real 
world, to be useful, VPMs must be capable to reproduce at least the measurable physi-
ological dynamics in critical care patients to the resolution and accuracy of the sensor 
readings [18, 114, 115]. The model input and output parameters should be embedded 
into the mathematics in the model structure describing known physiological dynamics. 
This requirement thus excludes black-box or generic models, such as neural networks. 
More directly, while it also ensures that the model captures fundamental physiology, it 
also sets a lower limit on model complexity.
Clinical relevance emphasises models able to be simulated in ‘clinical real-time’, the 
time between measurements and/or decisions. Model inputs should be the same as 
those used clinically in treating dysfunction, and outputs should be clinically measured 
variables relevant to guide care. Equally, it may use measurements not typically used, but 
for clinical uptake the advantages gained over typical approaches in terms of cost and 
workflow have to be justified. Hence, the model can fit directly into clinical care with 
inputs and outputs typically used to guide care, connected by model dynamics matching 
known clinical input–output responses of the physiological system, all of which ensures 
clinical relevance. Overall, the requirement of clinical relevance further delineates the 
possible model structures in size and complexity, where physiological and clinical rel-
evance also defines an optimal model complexity sufficient to warrant a broad rollout by 
the clinicians.
Identifiable treatment sensitivity is a crucial part in designing a virtual patient, as 
well as applying a VPM to titrate care. Perfectly, care is guided by a correctly predicted 
patient output in response to treatment inputs. In particular, for virtual patient models, 
the model output responses to specified model inputs can be used. Critically, sensitivity 
is defined as the “rate of change” of the output values in response to changes in the input.
For example, in glycaemic control, model-based assessment of insulin sensitivity 
relates input changes of insulin and nutrition, to expected glycemic response [36, 37, 41, 
44, 116–130], which can be monitored and its level and/or variation assessed relative to 
condition [88, 124, 128, 131–141]. Similarly, in mechanical ventilation, lung elastance 
determines how changes in the input “a controlled mechanical ventilation volume (pres-
sure)” transfers to the uncontrolled or independent output pressure (volume) response 
[78–80, 142–151], where this elastance is directly related to the work of breathing and 
ventilator driving pressure clinicians seek to reduce in titrating mechanical ventilation 
[148, 149, 152–156]. Again, similar, but simpler, measures of elastance are increasingly 
used to titrate care [148, 155–160].
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In a similar manner, output measures that reflect clinical goals in cardiovascular man-
agement, such as beat to beat stroke volume or stressed blood volume [71, 161–166], are 
increasingly called for clinically to guide care [167, 168]. However, current clinical meas-
ures can lack resolution and/or accuracy as they are typically estimated by surrogate 
measures, are typically measured only intermittently, and can require frequent recali-
bration during cardiovascular instability [168–173]. Model-based measures [71, 161] 
could be used to develop sensitivities for inotrope and/or fluid in a pharmacodynamics 
framework to better guide care with a high resolution model-based metric, as has been 
done for sedation-agitation management for example [174–176], but has not yet been 
addressed in this area.
Overall, these sensitivities provide only a few possible case examples. The only limi-
tation in creating these models and defining similar sensitivities is the required physi-
ological relevance in modelled dynamics, and ensuring the model can be practically 
and feasibly identified, and thus validated, with available clinical measurements [114, 
177–182].
In fact, because sensitivities capture patient condition in their response to care, they 
can be the clinical key in defining and monitoring the intra- and inter-patient variability 
that defines ICU patients, and thus to guiding therapy, as seen in [117]. They could thus 
be regularly obtained using such models as part of clinical practice to help assess patient 
state and response to care, given the advantage of computational models to use clinically 
available data and system identification methods to obtain a clinically useful sensitivity. 
In particular, highly sensitive patients need less treatment input or a smaller dose, and 
vice versa, thus providing a better metric on which to dynamically titrate patient-specific 
and personalised care. Hence, a physiologically relevant sensitivity metric modeling the 
relation of clinical input to patient-specific output response to treament is a crucial ele-
ment in improving care, regardless of whether models are used to identify this metric. 
In conclusion, this requirement further constrains the potential model structures and 
organisation, as the model must include such a sensitivity and it must be mathematically 
identifiable from the clinically available data [114, 177–184].
Identifiable from the data available follows immediately from this requirement and 
refers to mathematical criteria ensuring that the model parameters can be uniquely 
identified from the available patient-specific clinical data. Identifiability thus implies, 
that within a clinically relevant time frame a clinically relevant set of data is obtainable 
that can be used to identify patient-specific model parameters. More specific to virtual 
patients, this requirement implies it must be feasible to uniquely derive the sensitivity 
parameter, and all other relevant parameters, from measured clinical data. Thus, identi-
fiable sensitivities are critical in personalising models based on patient data at any given 
point in time. Pragmatically, with most metrics measured only intermittently and lim-
ited real-time data, only limited parameters can be uniquely identified. This limitation 
places an upper limit on model complexity, at least for direct, immediate use at the bed-
side (e.g. [70, 121, 177, 180–182, 185]).
This approach is also a minimal approach to the number of variables identified. 
Insisting on unique identifiability combined with typically limited or sparse data also 
helps ensure that a model is not over fit to the data. In particular, over fitting can be 
a major issue when more than one or a few model variables are identified as there is 
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trade-off between them, even if they are uniquely identifiable resulting in a model that 
does not accurately capture the dynamics or predict well. There are formalised analysis 
approaches using information criteria and/or practical identifiability analysis to aid in 
model selection and avoid over fitting and/or trade-off [177, 184, 186–190].
In contrast, increased model complexity can add clinical relevance and detail. Thus, 
models incorporating several to multi-million degrees of freedom can offer great insight 
into metabolic, pulmonary, cardiovascular, and, indeed, whole body systems (e.g. [15–
17, 19, 20, 27, 29–33, 38, 49, 56, 65, 67, 68]). However, especially given limited available 
bedside data, their parameter sets cannot necessarily be identified in real-time for use at 
the bedside in personalised care or virtual patients (to guide care) at this point. Impor-
tantly, this limitation does not stop the accrual of data to create a more patient-specific 
version of a more complex model, but does limit their immediate bedside use for guiding 
care, and thus the ability to create virtual patients, as well.
Given a suitable set or sets of parameters reflective of real patients, physiome mod-
els could have a role in protocol design in simulating real patient conditions with the 
required high or multi-scale level of detail [32, 33, 38]. Longer term, as care and data 
progress, enough data could accrue to create a patient-specific, potentially multi-scale 
bedside version of the physiome model [57, 191], particularly where there are emerging 
approaches to adapt model complexity to data availability that would unify this transi-
tion [192–194].
Overall, a VPM must contain all clinically relevant physiology and physiological 
dynamics to adjust treatment. Clinically relevant inputs and outputs including an iden-
tifiable sensitivity parameter must be included in the model structure. Over time, the 
evolution of these sensitivity profiles can quantify the intra-patient variability of the 
patient’s evolution over time as well as inter-patient variability. These requirements 
allow one to design VPMs, create personalised protocols in silico, and clinically imple-
ment those protocols to personalise care.
Figure  1 depicts a metabolic model and its defining equations developed to create 
virtual patients and design glycaemic protocols [121]. Model inputs include parenteral 






















Fig. 1 Glucose–insulin pharmacokinetic and pharmacodynamics model used for virtual patients
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dynamics, and the exogenous intravenous insulin input and its kinetics (uex(t)). The 
VPM structure comprises all relevant nutrition dynamics and insulin kinetics. The phar-
macodynamics equation for glycaemia, G(t), combines these inputs with the insulin sen-
sitivity, SI(t), to deliver a patient-specific glycaemic output response. Depending on data 
density insulin sensitivity can be identified hourly or more frequently. Patient specific 
dynamics and their evolution over time can then be reproduced [36, 99, 116, 118, 133, 
195, 196].
Similarly, Fig. 2 shows a simple pulmonary mechanics model that can be used to iden-
tify breath-specific and patient-specific elastance, the volume (or pressure) response to 
a controlled pressure (or volume) input in mechanical ventilation. This specific model 
has been validated on clinical data for both sedated and spontaneous breathing patients 
[142, 197–200]. As noted, the inputs are volume and flow (or pressure) with concomitant 
pressure (or volume and flow) independent outputs that are a function of the patient 
response to ventilation. The model sensitivity determined from these inputs is elastance 
as the sensitivity, discussed previously, which is used to guide care towards ventilation of 
patients at, in this specific example, minimal pulmonary elastance.
Last, Fig.  3 shows a specific model and equations for a model-based measure of 
stroke volume (SV) [161], based on similar prior models [201, 202]. Real-time SV has 
recently been identified in a consensus statement as a primary variable that would aid 
the guidance of circulatory management [167]. From this measure, a simple pharma-
codynamics models could be created using a standard approach validated in sedation 
management and other areas, including sensitivities to both inotrope and fluid therapy 
Fig. 2 Simple respiratory system ventilation model, where it is modelled as a combination of resistive and 
elastic components
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to aid cardiovascular and circulatory management. It could thus offer a new avenue of 
addressing key questions in circulatory management around assessing and managing 
fluid responsiveness and inotrope dosing that are currently major issues in the field (e.g. 
[167, 203–209]). Similarly, once there is a validated model with a uniquely identified sen-
sitivity, a virtual patient can be created to design and/or implement personalised, model-
based care.
When considering physiome models, each might be linked over time to these bed-
side models. Metabolic behaviour in Fig. 1 would, for example, be better informed by 
both circulatory and metabolic systems models, particularly in addressing diabetes. 
Pulmonary mechanics in Fig.  2 are tightly coupled with circulatory dynamics, and, 
equally, more detailed representations including outcome gas exchange [79, 210, 211] 
not addressed in just considering elastance and driving pressure, but related to outcome 
organ function. Finally, circulatory and cardiovascular management using models, like 
the one in Fig.  3, would be enhanced by more detailed circulatory dynamics in place 
of lumped parameters. Hence, a hierarchy exists, where this review focuses primarily 
on the virtual patient and thus the simpler modeling approaches, while noting that the 
overall idea of reproducible models used at the bedside will readily generalise to other 
levels and scales of models [57], as data becomes more dense and available.
In summary, the three core areas in this review all have models and/or emerging 
model-based measures that could be fitted into known model structures. The overall in 
silico or model-based approach, already in use in glycemic control and metabolic diag-
nostics, can provide a template for use in other areas, where first pilot and clinical tri-
als are commencing in the pulmonary case [77] and yet to emerge to the best of the 
authors’ knowledge in the cardiovascular case. Hence, the model definition provided in 
this section provides a means of evaluating models relative to available clinical data and 
the clinical application.
Fig. 3 Minimal cardiovascular circuit model used to identify beat‑to‑beat stroke volume (SV) or/and stressed 
blood volume (SBV), from which sensitivities to therapy could be developed to help guide care
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Data required for virtual patients
As illustrated in Fig. 4, virtual patients are derived directly from VPM and clinical data 
via system identification of model parameters (“Model types and requirements” section). 
To identify the desired sensitivities, data is required for all relevant inputs, e.g. for gly-
caemic control insulin and all forms of nutrition, for mechanical ventilation pressure/
volume inputs and positive endexpiratory pressure, and for cardiovascular monitoring 
the stroke volume and other measures of circulatory pressures and/or flows. Also neces-
sary are measurements of the clinically relevant and modelled output (e.g. glucose, vol-
ume/pressure, and stroke volume or other metric, respectively).
A wide range of methods is available to obtain a model-based sensitivity from this 
input–output data (e.g. [18, 118, 123, 212–222]). Tracked over time, it reveals the evolu-
tion of this patient-specific sensitivity to care and patient condition. This trajectory of 
sensitivity values, captured as a virtual patient, can consequently be employed to calcu-
late how new ways of administering interventions and care (e.g. insulin and/or nutrition) 
might lead to new, optimized, output results (e.g. blood glucose levels and/or variability), 
which in turn can be linked to clinical outcomes (e.g. [153, 223–233]).
A further important aspect of VPMs is ensuring relevant physiological and clinically 
observed dynamics are captured accurately. If the pathophysiological state of patients 
evolves slowly over time, then these parameters or sensitivities need only be identified at 
the same pace or slightly faster rate. Similarly, if clinical interventions only vary slowly or 
their effects can only be captured slowly due to limited or highly invasive measurements, 
then model parameters should be adapted at a similar rate. There is thus a balance 
between clinical measurement/intervention rate, and the underlying rate of physical 
change that can be observed with the data available, and thus identified and validated.
Dysfunction in most ICU patients is typically characterised by fast changing dynam-





















Virtual Trials GlycemicControl Outcomes
VIRTUAL PATIENT GENERATION
VIRTUAL TRIAL SIMULATION
Fig. 4 Virtual patient and cohort creation (top) and virtual trials process (bottom) for a metabolic model and 
system, but generalisable in model and inputs/outputs to any other similar case
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inter-patient variability in response to care. Thus, the data must be measured with a fre-
quency enabling the identification of these differences in level and rates of evolution in a 
clinically useful timeframe. However, measurement frequency is subject to a trade-off on 
clinical workload and quality of care, especially if the data must be manually obtained, 
entered and/or managed [106, 234–236]. Thus, such an approach also opens the next 
technological door towards electronic and automated sensing, and eventually, closed 
loop care systems, as recently emerging with the artificial pancreas in type 1 diabetes 
[237–249].
Thus, input and measured data must be available at rates appropriate for successfully 
revealing the observed and model dynamics, which in turn opens new technological 
opportunities around continuous or automated sensing and data management. If meas-
urements are not frequent enough, the model may miss important changes in patient 
state and trends to be useful in guiding care. Fortunately, many clinical sensors currently 
deliver data more frequently than necessary, e.g. cardiovascular pressure catheters pro-
viding pressure signals almost continuously, or respiratory pressure and/or flow wave-
forms are equally sampled at 100–400 samples per second. Further, more and more ICU 
sensors provide electronic interfaces, allowing automated data access at appropriate 
rates using standard data acquisition (e.g. pressure signals from a catheter or glucose 
measurements from a continuous glucose monitor (reviewed for ICU in [250]), signifi-
cantly reducing the data acquisition workload [234, 251]. Hence, increasingly, it is “only” 
required to guarantee, that the combination of models and data bring about accurate 
model-identified estimates of the physiological sensitivities and its evolution.
Overall, it can often be assumed that there is likely to be sufficient and relevant data 
for all the core areas of care considered here, for which a virtual patient and model-based 
approach might have impact. Thus, rapidity of data acquisition is not an issue. Equally, 
it is important to understand the error and/or bias in any sensor to avoid over fitting a 
parameter, providing an upper limit for the resolution of identified parameters and num-
ber of model dynamics required. This upper limit can be informed a priori using existing 
methods [186, 187], and should also be informed by the underlying knowledge of the 
physiology. Thus, the size of the model and the ability to identify it remain an issue, but 
one that increasing data, along with coupling to the bedside scale models discussed in 
more detail in this review, could be ameliorated in a multi-scale approach [191].
Finally, despite increasing ease to gather data, there is also increasing need for data by 
researchers. This issue creates the opportunity for data sharing to significantly enhance 
potential research gains using emerging big data informatics and machine learning, for 
example. Thus, this review would recommend that groups with large databases consider 
how data could be safely and ethically shared as is done for example by the ELIXIR data-
base and others in the EU [252, 253].
Virtual patients, virtual cohorts, and their validation
To this point, the needs and requirements for models, parameter identification meth-
ods, and measured clinical data are covered. The metabolic management space is the 
furthest, having profited from decades of modelling around understanding, diagnosing 
and controlling diabetes mellitus in outpatients (e.g. [18, 41, 99, 129, 196, 241, 242, 245, 
248, 254–257]). Pulmonary modeling for managing mechanical ventilation is emerging 
Page 12 of 29Chase et al. BioMed Eng OnLine  (2018) 17:24 
towards its first RCT [77], although many models exist (e.g. [28, 78–80, 211, 258]), and 
cardiovascular and circulatory management is more complex and still emerging. Hence, 
this section has more focus on the validation of metabolic models and systems, as an 
example, with broader reference to the needs and requirements applicable to any such 
model in other areas.
Virtual patients
Figure  4 shows how virtual patients can be created, where the trajectories of model-
based sensitivities offer significant clinical and/or physiological insight independent 
of any use in the model. It is important to understand virtual patients represent those 
patient’s specific responses, implicitly encoded by the model structure and parameter 
values identified from the patient data. If the model structure is appropriate and param-
eters accurately identified, the outputs will reflect patient-specific condition and evolu-
tion. Thus, comparing these trajectories over different conditions offers added insight, 
e.g. comparing patients with and without a given drug therapy [25]. While, to date, such 
analyses are limited, the growth of accessible data should enable much more rapid use 
of model-based sensitivities for research insight and in virtual patients to improve care.
In metabolic systems, insulin sensitivity trajectories have captured the impact of other 
drug therapies [132, 259], provided insight into the evolution of patient condition over 
time and thus provided hints how to target better treatment [131, 133, 139], and diag-
nosed the absence of sepsis [88]. In pulmonary mechanics model-based elastance has 
been investigated to reveal the impact and effect of recruitment manoeuvres and how 
they decline over time [152, 260, 261]. The impact of different breathing modes and 
recruitment manoeuvres [80, 142, 147, 261–263], where clinically assessed, simpler 
elastance metrics have been insufficient [264]. In the cardiovascular area, model-based 
methods of determining beat to beat stroke volume or stressed blood volume [71, 161], 
and other more detailed lumped parameter physiological models used for real-time 
diagnosis (e.g. [265–268]), have been created with the eventual use to study the effect 
of inotrope, dosing fluid management with a long term goal of having virtual patients 
emerge in this area, where further patient-specific guidance would add significant value 
to a difficult clinical problem [162, 167, 269].
Thus, VPMs and derived virtual patients create an opportunity for defining and opti-
mising new protocols and consequently methods to optimise care. In this way, several 
protocols for metabolic control have been optimised, at least in part [36, 72, 76, 84, 
90, 128, 239, 270–273], and some have gone on to show clinical results very close to 
those simulated before implementation [90, 274, 275]. Virtual patients can thus be used 
to enhance protocol development, as well as to create patient-specific protocols using 
direct modeling and, in some cases, management of the inter- and intra-patient variabil-
ity in risk-based treatment decisions [72, 84, 85, 89, 119, 120, 128, 270]. Particularly in 
the glycaemic control, failure to manage patient variability due to the application of fixed 
protocols has been shown to contribute significantly to the failure of large clinical trials 
[117]. This evidence is in strong support of the use of virtual patients to develop proto-
cols that directly manage patient variability in ways clinically derived protocols cannot.
Equally, virtual patient models can also be used to analyse existing protocols. Numer-
ous possibilities include testing protocol variations, including timing, sensor errors, 
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errors in dosing, other inputs, and patient variability [36, 101–103, 117, 135, 276], or 
even the development of robust sensor data management and alarms [277, 278]. In par-
ticular, it should be noted that while sensor models are not in the scope of this review, 
there is a rich literature on validated sensor and device models, which can play a key 
role in these simulations (e.g. [118, 279–291]). Virtual patient models can also be used 
to test model assumptions, such as the impact of fixed, unidentifiable physiological 
model parameter values on performance and/or control when they cannot be identified 
from the available clinical data [36, 101, 292–295]. Hence, virtual patient models can 
test model assumptions, the impact of expected or unexpected physiology, the impact of 
delivery or sensing technologies, or any combination.
Finally, it might be worthwhile to note that all these methods used to create virtual 
patients have a sound basis over decades of physiological modelling and parameter 
identification of physiological parameters for research studies. The concept of virtual 
patients, which to the best of the authors’ knowledge was first introduced for designing a 
protocol for a standard of care in [272], has significantly extended these early works and 
can be found in other patient simulators and models (e.g. [85, 99, 102, 123]). In fact, a 
recent analysis about future ICU research noted its current critical failures, mainly, too 
often syndromes and specific cohorts are studied that do not generalise and that perhaps 
in the future “single patient trials” may become more important [91, 93]. Virtual patients 
capture these single patient trials in silico, and can be used in real-time for decision sup-
port in personalised, model-based protocols, uniquely treating each individual patient in 
a personalised “one method fits all approach” or single patient trial.
Virtual cohorts
Virtual cohorts are simply collections of virtual patients. Since virtual patients can be 
derived from any group of useful and clinically relevant patient data, virtual cohorts can 
be designed to be as specific, or, more relevantly, as general as possible. Thus, a virtual 
cohort can be derived from any such collection of relevant patient data. The data should 
be as representative and complete as possible of the targeted treatment group or cohort, 
while ensuring it contains all reasonably expected patient states, patient dynamics and 
evolution of patient condition, which might occur in practice. Thus, broad and typical, 
where many randomised trials have very focused and thus potentially atypical cohorts 
[91].
For example, a glycaemic control virtual cohort with none of the rapid rises or changes 
in insulin sensitivity that lead to hypoglycaemia and its associated risks in treatment 
and outcome, would not be representative of observed clinical results to date. The same 
would hold for the other areas of analysis considered here, including but not limited to 
sudden desaturation events or the impact of proning, a controversial topic [296, 297], in 
ventilation on the overall effective respiratory elastance, or the impact of sudden changes 
in circulatory dynamics. It is the authors’ experience in applying virtual patient models 
to design protocols and clinical trials, and then implementing them in model-based care, 
that, in fact, to ensure patient safety and protocol robustness, it is better to slightly over 
represent outlying cases than to under-represent or miss them.
Consequently, a virtual cohort should cover all clinically relevant patient dynam-
ics observed in care, similarly to the physiological model and clinical data that should 
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represent all relevant patient dynamics observed in care. Failure to comply with this 
constraint implies a potentially skewed protocol design due to the missing dynamics 
and thus imposes additional risk to either safety or performance during deployment 
of a protocol created using this approach. Equally, a skew towards outliers or a certain 
behaviour that is not representative of the treatment cohort itself can also provide bias 
in the protocol. This choice may be acceptable as long as all dynamics are represented as 
any in silico design could ensure robustness across those dynamics in the virtual patient 
cohort. Thus, these cohorts and episodes should be broad enough in patient numbers 
and patient diagnosis to capture all clinically observed dynamics, particularly outlying 
effects or cases. They must also accurately represent what would be found in ICU prac-
tice, so that simulations of these virtual cohorts implementing virtual trials yield results 
that match what is seen, or would be seen, in practice.
The research relevance of this latter point is important as a recent analysis on the state 
of ICU research noted that clinical trials with limited cohorts often do not generalise 
to broad cohorts and typical care situations [91]. Virtual cohorts enable the design of 
effective, general protocols for the typically diverse cohorts seen in practice, yielding 
a model-based and personalised “one method fits all” form of care that robustly trans-
lates to all or most patients [273, 298]. The resulting protocols thus offer the ability to 
design and conduct clinical trials with greater confidence in the ability of the results to 
generalise.
Virtual trials (Fig.  4) give model-based indications of likely safety and performance 
outcomes for protocols tested on a particular virtual cohort. Virtual trials require either 
a treatment independent sensitivity, such as insulin sensitivity in the glycaemic control 
case, or some way of capturing changes in this sensitivity with time and/or treatment 
interventions. In the case of the pulmonary modelling, a short or longer recruitment 
manoeuvre that results in improved lung recruitment will change the underlying 
elastance sensitivity, or volume response to pressure (or vice versa), but can be used in a 
protocol to identify a current state and select care. Capturing how these changes in vir-
tual patient based virtual trials on a per-patient or cohort basis is the subject of ongoing 
work in the field.
Validation: ensuring the model is “Good”
The critical question with any modelling approach is how to verify if the model is valid 
in capturing the clinically observed relevant dynamics? Fitting a model to data does not 
guarantee the identified sensitivity parameters and resulting patient-specific model will 
accurately capture the patient-specific response to care. Due to model complexity, cur-
rently the only practical approach to test validity and thus the identified, patient-specific 
model parameter values is to test if the identified model accurately predicts the outcome 
in response to a new clinical input. This test clearly shows whether the patient-specific 
model and parameter values have accurately captured the patient-specific condition. 
But, how do we best and with least effort validate such virtual patients and models in 
practice?
This review proposes three increasingly rigorous validation tests to assess the validity 
and thus clinical utility of a model and virtual patient cohort:
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  • Patient level A patient-specific model can be identified form a series of clinical 
data at a given moment in time, from which the outcomes from subsequent clini-
cal inputs can be simulated. Predicted, patient-specific outputs are compared to the 
measured patient data testing the predictive validity of the virtual patient model. This 
test assumes an accurate identification resulting in accurate prediction of the patient-
specific sensitivity and patient dynamics. However, since patient-specific condition 
changes over time, within the range of intra-patient variability this test thus validates 
the patient-specific VPM dynamics.
  • Cohort level before-after Given a virtual cohort a specific protocol can be simulated 
and outcomes compared to prior or later application of the protocol in clinical use. 
Comparing statistical cohort results (median and variability) and individual patient 
median results assesses if virtual patient model accurately captures cohort dynamics 
(median and variability) and the central tendency of the individual patients in that 
cohort. This test validates the models and parameter identification methods over 
a cohort and specific, individual virtual patients over an entire episode or stay, and 
thus the overall approach. However, it does not validate specific patients beyond cen-
tral tendency of their outputs.
  • Cohort level cross validation This validation test uses data from multiple clinically 
matched cohorts (typically by severity score, diagnosis or other patient metric) to 
create matched virtual cohorts. These virtual cohorts can be tested on the original 
protocol they were given, providing a “self validation” assessing model errors, as 
above. Cross validation tests the virtual patients of Cohort A on the protocol given 
to Cohort B with results compared to the clinical results for the (matched) Cohort 
B, and similarly so for any other cohorts (C, D, etc.). The other cohorts are treated 
similarly. Figure 5 illustrates the approach. The quality of outcome at the cohort and 
per-patient levels of each cross validation test can be compared to clinical data from 
a clinically matched and thus equivalent cohort. These tests assess the independence 
of the identified patient-specific, model-based sensitivities from the data used to cre-
ate these virtual patients, including their ability to accurately model the underlying 
Cohort B B                B
B               A
B clinical data
Self simulaon of B
Cross simulaon of B
Cohort A A                A
A               B
A clinical data
Self simulaon of A




Fig. 5 Virtual trial scheme for self‑ and cross validation example for the two cohorts and protocols
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patient dynamics so they provide the expected/same results, as the matched clinical 
cohort when treated with another protocol.
These three validation tests assess the validity of the model, the identified patient-spe-
cific sensitivity parameters, and the ability to accurately design protocols that clinically 
produce the same results seen in silico at both the patient and cohort levels. The cohort 
level allows accurate in silico estimation of clinical performance of the protocol when 
used. The patient level allows accurate evaluation of safety or outlying events, which 
occur to selected patients in a cohort. Together, these validation tests ensure virtual 
patient and model validity by ensuring that using them to design a protocol will deliver 
the same results clinically.
Examples of the first form of validation are found in [121] and have been applied in 
multiple studies [36, 123, 276]. Importantly, these validation tests do not focus on model 
fit to data, but the ability to adequately predict a wide range of clinical outcome metrics, 
or simply, the ability of the model to generalise. Similarly, pilot trials can be used in this 
form of validation, where targeted clinical data is collected prospectively using a model 
and protocol (e.g. [89, 299]).
At the patient level, predictions are only as accurate as the ability to capture varia-
tion in patient state over the addressed relevant time interval. Assessing the range of 
error allowable or likely for intra-patient variability can be done, for example, using sto-
chastic models that provide estimates of the range of intra-patient variability [117, 120]. 
There is also significant work in the area of type 1 diabetes modeling assessing variabil-
ity of model parameters including physiological and behavioural changes using Bayes-
ian virtual patients and cloning and statistical models [300, 301], which are part of the 
validation of the Padova type 1 diabetes simulator [99] recently approved for use in some 
regulatory submissions. However, since many intra-patient variations over a reasonable 
interval are relatively small, patient level prediction is thus a basic first validation step of 
the model and sensitivity values, because the ability to capture physiology by predicting 
outcomes to clinical inputs is a critical first element.
Cohort level before-after validation has only been presented, to the authors’ best 
knowledge, twice [90, 274]. The main desired goal is to predict cohort level median 
response and variability (e.g. interquartile range and/or 90% range). This requirement 
thus wants a model to capture the first and second order cohort level statistics critical to 
understanding protocol performance and overall risk, and, ideally, also the per-patient 
central tendency (e.g. median) statistics, as well.
Successful, before-after validations illustrate how in silico protocol design can accu-
rately capture the outcomes of clinical trials, well in advance of the actual clinical use, 
enabling far faster and safer protocol design. Hence, this form of validation also illus-
trates the potential of virtual patients in designing safe, effective and personalised new 
treatment approaches. While such models are now emerging in other areas than glyce-
mic or metabolic control, the requirements noted above could be seen, at this point, as 
being general across these areas.
Cohort level cross validation has only been demonstrated twice [116, 302], and could 
be viewed as the most rigorous form of model validation, requiring extensive data 
and trials in the area even to enable the test. Good results comparing both cohort and 
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per-patient median response in this study validated the underlying model assumptions, 
showing the identified sensitivity parameter, in this case insulin sensitivity [116], was an 
accurate representation of patient condition and evolution at a cohort and patient level, 
independent of the clinical inputs used to identify that value. The second case presented 
this evidence across three independent ICU cohorts and different clinical practices for 
two protocols, one model-based and one local clinical protocol [302]. These outcomes 
thus more conclusively validated these models, methods, and overall virtual trials 
methodology.
In summary, this section presents three forms of model validation, trying to answer 
the essential question of “how good are the model and virtual patients created?” The 
three tests presented are in increasing order of rigor, and provide increasing levels of 
confidence to a user that the model and virtual trial outcomes will be the same when 
used in clinical practice. They also require increasing data from pilot or clinical trials, 
and thus would be obtained as a field matures, where, in this case, the metabolic mod-
eling area is mature and the cardiovascular area is still emerging only now at the first 
level, for example. However, the overall tests themselves are general and should be appli-
cable to any virtual patient model, method, and eventual virtual trial.
Further and future possible implications: economics and decision making
This review has presented virtual patients primarily from the viewpoint of their tech-
nical potential to solve medical problems in terms of their use to develop, design and 
clinically apply novel therapeutic approaches. The ability to use their underlying models 
and identified patient-specific parameters as model-based sensors better assesses patient 
state and can predict the potential response to therapy. However, these technical and 
clinical advantages might also flow-on to significantly affect the economics and decision 
making in health care.
In addition, given the ability to reasonably predict the response to an intervention, 
whether in real-time or over a virtual cohort, then it would be possible to ascertain the 
cost of care or required change in care. Any intervention has a cost, including the per-
sonnel required to administer it. For glycemic control, these costs may be relatively low 
for glucose sensing and insulin, although the time cost of care can be high [234]. On 
the other hand, the cost and clinical impact of catheters in cardiovascular monitoring 
(e.g. [303–307]) or added cost of each mechanically ventilated patient day [308] can have 
large impacts on the cost and outcome of care, so the ability to optimise their use and 
improve outcomes could help alleviate cost pressures. Studies have associated improved 
levels of glycaemic control with net cost savings [309, 310], at least some of which might 
be predicted in simulation. Hence, the ability to understand the number of interventions 
and devices required for a cohort, using virtual trials and locale specific cohorts, could 
lead to better understanding and/or predicting some of the significant contributors to 
the cost of care. Overall, as such frameworks emerge, it could become possible to assess, 
monitor, and track the cost of ICU care in particular settings. A virtual trial framework 
for protocol design may consider not only for improvements in care and outcome, but 
also optimisation of resource utilisation in a specific setting.
Finally, as virtual patient methods with the ability to model and predict the response 
to care improve, it may become possible to determine the impact, or futility, of care. In 
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glycemic control it is already possible to assess a resistance to insulin therapy in some 
patients. While hyperglycemia is well associated with increased risk of poor outcome 
and mortality, it does not in any way imply futility for all care of that patient. However, 
in future, across multiple organ systems and modes of care, it may become more pos-
sible to assess overall patient outcomes, creating both the opportunity to avoid prolong-
ing ineffective care, as well as generating significant ethical debate around the legitimate 
uses and scope of technology in decision making.
Conclusions and overall summary
The combination of engineering and computer modelling approaches has revealed great 
potential in intensive care medicine. Easier, more frequent access to data allow increas-
ing ability to utilise computation to enable the model-based design and implementation 
of better protocols/procedures enabling improved, personalised care. The methods used 
to design virtual patients and cohorts reviewed in this article are the emerging tip of a 
much larger iceberg in personalised, and potentially increasingly automated, care in the 
ICU, and eventually in less acute and out-patient care.
Personalised, patient-specific precision medicine is widely tipped as the next major 
advance in health care. The transition from “one size fits all” protocols with little or no 
adaptation to manage intra- and inter-patient variability to personalised, time-varying 
“one method fits all” approaches will enable better care and thus improved outcomes 
compared to current non-computerised care, which lacks the capability to process the 
available clinical data to achieve these goals. Hence, one immediate and critical key ele-
ment in achieving these goals is the development and increasing use of robust, accurate 
virtual patient models and methods addressing major areas of ICU and chronic disease, 
including the metabolic, pulmonary and cardiovascular systems, as reviewed here.
In particular, the merger of increasingly available clinical data and engineering model-
ling can create virtual patients and cohorts, which, properly validated, can be used to 
analyse, design and optimise care, while maximising safety and performance. They also 
offer the opportunity to test the potential of new devices and drug therapies in silico, far 
faster and more safely than via a clinical trials based approach, saving time and reduc-
ing risk. This review has thus delineated the types and structure of models necessary, 
including the need for key sensitivity parameters, defined the required and increasingly 
easily obtained clinical data, and, critically, proposed three levels of model validation to 
ensure the resulting virtual patients and cohorts are safe, accurate and clinically relevant. 
The overall result creates a clear outline of the state of the art in each area and their 
interaction.
In future, virtual patient cohorts might be readily collected and curated from increas-
ingly deployed central electronic patient data management services, for open access use 
by researchers, industry and/or regulatory bodies. They enable not only in silico testing 
of new treatments and/or devices, but also the potential for standard in silico testing 
for regulatory approval. In addition, more rapid design and optimisation of personalised 
care approaches may well yield significant economic and social benefits from improved 
productivity in care and patient outcomes.
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